Opus Genetics (IRD) Earnings Date & Reports

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

IRD is expected to report earnings to rise 2.64% to -14 cents per share on November 17

Opus Genetics IRD Stock Earnings Reports

Q3'26

Est.

$-0.14

Q2'26

Beat

by $0.02

The last earnings report on August 06 showed earnings per share of -14 cents, beating the estimate of -15 cents. With 807.06K shares outstanding, the current market capitalization sits at 420.14M.

View a ticker or compare two or three

IRD

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for IRD